Ocugen, Inc. (OCGN) Earnings Call Analysis

NASDAQ · Healthcare · Biotechnology

8/25

Growth 2 Margin 0 Expansion 3 Platform 1 Financial 2

latest quarter score

Earnings Reports

8
Ocugen (OCGN) Q2 2026: $130M Financing Extends Cash Runway, Three Late-Stage Gene Therapy Programs Advance
August 06, 2026
8
Ocugen (OCGN) Q1 2026: $37.5M Capital Raise Extends Runway as Three BLA Filings Targeted by 2028
May 05, 2026
10
Ocugen (OCGN) Q4 2025: OCU410 Shows 46% Lesion Reduction, Accelerating Gene Therapy Pipeline Milestones
March 04, 2026
7
Ocugen (OCGN) Q3 2025: $20M Financing Extends Runway, OCU400 Nears Phase 3 Completion
November 05, 2025
8
Ocugen (OCGN) Q2 2025: Operating Expenses Drop 8% as Multiple Gene Therapy Trials Hit Milestones
August 05, 2025
7
Ocugen (OCGN) Q1 2025: R&D Spend Jumps 40% as Modifier Gene Therapy Portfolio Advances Toward 3 BLA Filings
July 07, 2025
Ocugen (OCGN) Q4 2024: FDA Alignment Accelerates Stargardt Trial, Extending BLA Pipeline Visibility to 2028
March 05, 2025

Browse all companies